NFE2L2 and neoplasm: While NRF2 activation provides cytoprotection and suppresses carcinogenesis under physiological conditions, persistent NRF2 stabilisation—frequently due to mutations in Keap1 or NRF2—promotes tumour survival, metabolic adaptation, and chemoresistance [14].